Publicaciones en colaboración con investigadores/as de Charles University in Prague (18)

2023

  1. Worldwide survey on implantation of and outcomes for conduction system pacing with His bundle and left bundle branch area pacing leads

    Journal of Interventional Cardiac Electrophysiology, Vol. 66, Núm. 7, pp. 1589-1600

2020

  1. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial

    Osteoporosis International, Vol. 31, Núm. 10, pp. 1935-1942

  2. Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

    Neurology and Therapy, Vol. 9, Núm. 2, pp. 443-457

2019

  1. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

    Archives of Osteoporosis, Vol. 14, Núm. 1

2018

  1. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

    Journal of Bone and Mineral Research, Vol. 33, Núm. 5, pp. 783-794

  2. Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray–Based Bone Assessment Techniques

    Journal of Bone and Mineral Research, Vol. 33, Núm. 12, pp. 2230-2235

2017

  1. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1367-1376

  2. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

  3. Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial

    Journal of Bone and Mineral Research, Vol. 32, Núm. 5, pp. 1040-1051

2016

  1. Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture results of a randomized, active-controlled, double-blind clinical trial at 26 weeks

    Journal of Bone and Joint Surgery - American Volume, Vol. 98, Núm. 22, pp. 1868-1878

  2. Effets du tériparatide et du risédronate sur la DMO et la consolidation fracturaire chez des patients âgés avec fracture pertrochantérique récente: Résultats finaux d'un essai clinique randomisé de 78 semaines

    Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A83-A84

  3. Teriparatide for osteoporosis: Importance of the full course

    Osteoporosis International, Vol. 27, Núm. 8, pp. 2395-2410

2015

  1. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 373, Núm. 3, pp. 232-242

2014

  1. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment

    Bone, Vol. 59, pp. 139-147

2011

  1. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis

    Bone, Vol. 48, Núm. 5, pp. 972-978

2010

  1. The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density

    Osteoporosis International

2009

  1. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis

    Journal of Bone and Mineral Research

  2. Response to comparison of teriparatide and strontium ranelate in postmenopausal women with osteoporosis

    Journal of Bone and Mineral Research